122 results about "Allergic transfusion reaction" patented technology

The invention relates to a class of CpG immunostimulatory oligonucleotides containing a CpG immunostimulatory motif and a second motif which is capable of forming secondary structure, including duplex and higher order structures, in vitro and in vivo. The oligonucleotides of the invention are useful as adjuvants in vaccination. The oligonucleotides are also useful for inducing an immune response, inducing expression of a type I interferon (IFN), inducing expression of gamma interferon (IFN-gamma), and for treating a variety of conditions, including allergy, asthma, infection, and cancer.

The invention provides a compound betamethasone suspension injection, which is a compound preparation composed of low-solubility betamethasone dipropionate and high-solubility betamethasone sodium phosphate. Long-lasting, it can be used for the treatment of musculoskeletal and cartilage tissue diseases, allergic diseases, skin diseases, collagen diseases, tumors and other clinical diseases.

The invention discloses a preparation method of an anti-bacteria non-woven fabric and an antibacterial agent. The anti-bacteria non-woven fabric is prepared by comprising the steps of: dissolving chitosan by using lactic acid to prepare the chitosan solution; dissolving zinc lactate in deionized water to prepare the zinc lactate solution; mixing the chitosan solution with the zinc lactate solution to prepare the antibacterial agent; and modifying a non-woven fabric in an antibacterial way: adding the antibacterial agent on the non-woven fabric, drying to prepare the anti-bacteria non-woven fabric. According to the second part of antibacterial performance of fabrics in GB / T20944.2-2007, the anti-bacteria non-woven fabric prepared by the invention has bacterial inhibiting ratio more than 99 percent through absorptive method detection, is qualified through skin irritation and vagina mucosa irritation and skin allergic reaction irritation tests, and meets sanitation requirements on sanitation standard GB15980-1995 of disposable medical supplies and sanitation standard GB15979-2002 of disposable hygienic products.

Invented is a method of inhibiting the activity / function of PI3 kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.

The invention relates to the use of human lysozyme in pharmaceutical industry, in particular the use in preparing medicines for treating dermatosis, infection and ulceration caused by bacteria, fungus, viruses, allergic reaction, and occupational diseases, physical diseases, nerve dysfunctional diseases, and immunity diseases. The invention exploits the novel use of human lysozyme in medical treatment, the gene recombination lysozyme has rich source, the invention also features simple process for manufacturing, and ease in use.

The invention relates to a medicine, in particular to broad-spectrum and high-efficiency antibacterial washing liquor and a preparation method thereof. The invention is characterized in that the antibacterial washing liquor is prepared by the following materials according to the weight ratio: 0.0001-2.0 of N-coconut-oil fatty-acid acyl L-arginine ethyl ester DL-pyrrolidone carboxylate, 0.0001-1.0 of dodecyl dimethyl benzyl ammonium chloride, 10.0-99.995 of water, and the balance of auxiliary materials. The broad-spectrum and high-efficiency antibacterial washing liquor has the following characteristics and advantages that pathogenic microorganisms are killed in a broad-spectrum and high-efficiency manner; ureaplasma urealytium, gonococcocci and trichomonas vaginalis can be killed in one minute; the killing rate for escherichia coli, staphylococcus aureus and candida albicans is respectively more than 99%; non-toxic; no stimulation is caused to the skin; no allergic reaction is caused; no stimulation is caused to the eyes; no stimulation is caused to vaginal mucosa; and the pH value of a preparation is close to that in the normal vagina.

The invention relates to a novel 5, 6, 7- tri-oxygen Dihydroflavonol, shown in formula (1), the preparation method and its application. The compound can be used to prepare drug combination that can prevent hepatitis b, protect liver, treat fungal infection, prevent diseases that generates free radical during disease change including inflammation, autoimmune diseases, radiotherapy sequela, tumor, myocardial ischemia, cardiac hypertrophy, aging, allergic reaction and atherosclerosis. There are various preparations for said drug combination.

The invention relates to a medicine for treating allergic rhinitis, which takes radix astragali, divaricate saposhnikovia root, atractylodes rhizome, grass leaf sweelflag rhizome, cocklebur fruit, angelica root, Chinese angelica, szechuan lovage rhizome, cassia twig, radix paeoniae alba, gizzard-membrane of chicken, large-leaved gentian, rhizoma atractylodis, amur corktree bark, tuckahoe, chrysanthemum and liquorice as raw materials; the raw materials are added with water and decocted to be concentrated into thick paste; after that, the thick paste is dried and ground, and then is filled intocapsules; finally, after being sterilized, the capsule product can be prepared. The medicine has the functions of warming lung and tonifying spleen, eliminating evils and activating organs as well asactivating blood circulation to dissipate blood stasis, is used for treating the allergic rhinitis with reliable, rapid and convenient treating effect, is safe to take, and has the total effective rate of 96.9% through clinical observation.

A use of ammonia oxidizing bacteria in the manufacture of a medicament and a method for treating a subject who has developed or is at risk of developing at least one of hypertension, hypertrophic organ degeneration, Raynaud's phenomena, fibrotic organ degeneration, allergies, autoimmune sensitization, end stage renal disease, obesity, diabetes type 1, osteoporosis, impotence, hair loss, cancer, aging, autism, and an autism spectrum symptom comprising positioning ammonia oxidizing bacteria close proximity of a surface of the subject, of nitric oxide and nitric oxide precursors using ammonia oxidizing bacteria.

The invention discloses an ecological gynaecological externally-applied medicine composition and a preparation method thereof. The preparation method of the composition comprises the steps of conducting sterilization on glucose, tween 80, dipotassium phosphate, sodium acetate, seven-molecule crystal water magnesium sulfate, manganese sulfate, ammonium citrate tribasic, soluble starch and yeast cream, inoculating probiotics liquid, and conducting fermentation, so that a lactobacillus fermentation culture is obtained; adding one or more types of medicinally acceptable additives to the culture, so that the ecological gynaecological externally-applied medicine composition is obtained. The ecological gynaecological externally-applied medicine composition can be used for adjusting ecological balance of the external genital tract of a woman and preventing and treating female vaginitis. Experimental results show that the medicine composition has the inhibition and killing effects on staphylococcus aureus, colon bacillus and candida albicans, no irritation is caused to skin, and no skin allergic reaction is found.

The invention belongs to the field of immunodetection and provides a method for diagnosing bovine tuberculosis mediated by a recombinant protein mixture and a regent for diagnosing bovine tuberculosis mediated by the recombinant protein mixture; the reagent comprises the recombinant protein mixture used as specific irritant; animals infected by mycobacterium bovis can be simulated by the recombinant protein mixture so as to generate a DTH (delayed type hypersensitivity) reaction; compared with a PPD (purified protein derivative) intradermal allergic reaction test, a intradermal allergic reaction test established by regent provided by the invention has higher specificity; mycobacterium bovis infection can be distinguished from environmental mycobacteria infection; and therefore, the method and the reagent can be effectively used for clinical detection of the bovine tuberculosis.

The invention discloses a traditional Chinese herbal preparation for treating chronic nasosinusitis, which consists of gypsum, honeysuckle, chrysanthemum, ligusticum wallichii, radix angelicae, mint, dried tangerine, figwort root, spina gleditsiae, radices sileris, radix rehmanniae, angelica sinensis, pollen, magnolia flower, Siberian cocklour fruit, platycodon grandiflorum, radix bupleuri, radixscutellariae, herba pogostemonis, radix puerariae, bighead atractylodes rhizome and liquorice, the medicines are composited to generate a synergistic effect of all the medicine efficacies, and the preparation has the effects of opening the inhibited lung-energy, dispelling pathogenic wind, clearing liver fire, cooling and activating blood, eliminating stagnation and discharging pus. The traditional Chinese herbal preparation adopts the pharmacological basis on treating chronic nasosinusitis that: by aiming at the etiological pathology of the chronic nasosinusitis, the traditional Chinese herbal preparation prevents bacteria, diminish inflammation, avoid allergic reaction, improve immunity of the organism and microcirculation, and promote tissue cell repair. The preparation of the invention not only is in accordance with the principle of medicine and health syndrome differentiation and treatment in China, but also is supported by modern pharmological study, so the curative effect is obvious; and the preparation has no toxic or side effect, stable long-term effect and convenience for taking, and is worth being popularized.

The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish as needed a transitory helminth infection and or to simulate in a parasitic helminth infection with helminth excretory and secretory products (ESP), thereby having immunosuppressive effect against benign antigens and or stimulating a regulatory immune response characterized by the production of T helper cells 2 (Th2), T regulatory helper cells (TReg) and certain cytokines, including, but not limited to interleukin 10 (IL-10), as a therapy or prophylaxis of allergy and other IgE-mediated disorders, which are marked by an inappropriate immunoglobulin E (IgE) immune response including, but not limited to an abnormal IgE antibody production to benign antigens. The invention presents using helminth compound by administering it in a frequency and amount sufficient to eliminate or ameliorate the inappropriate immune response in an asthmatic and or allergic individual. This invention is generally directed to diseases IgE antibody-mediated disorders, including asthma, allergies, hypersensitivity and anaphylactic reactions. More specifically, the present invention is directed toward the treatment of certain common food allergies, such as an allergy to peanut, tree nut, milk, egg, wheat, and shellfish (CFA's).

The invention discloses a stable granular medicine composition containing epinastine or hydrochloride thereof. The stable granular medicine composition also comprises a binding agent which has a stabilizing effect on the epinastine or the hydrochloride thereof. Meanwhile, the invention also discloses a preparation method of the stable granular medicine composition. The granular medicine composition disclosed by the invention can also be used as a medicament which urgently needs to be developed in clinic and has an excellent effect on allergic reaction diseases of children.

The invention discloses a pseudolaric acid B and the application of derivative thereof in the preparation of immunity inhibitor. Experiments prove that the pseudolaric acid B and the derivative thereof have excellent immunity inhibiting effect and lower toxicity, so that the pseudolaric acid B and the derivative thereof or pseudolaric acetate and salt of the derivative of the pseudolaric acid B can be taken as medicine for preventing or treating exclusive reaction, autoimmune disease, inflammatory disease, allergic disease and the like which are related to immunity and caused by organ or skin grafting of mammal (especially human beings).

The invention relates to a pharmaceutical composition for treating asthma, allergic reaction and inflammation. The composition comprises a leukotriene antagonist, antihistaminics and medicinal carriers, wherein the leukotriene antagonist is Montelukast and salts thereof, and the antihistaminics is olopatadine hydrochloride and salts thereof. The composition is suitable for preventing and long-term treating of asthma for children and adults, and can treat asthma patients sensitive to aspirin, prevent bronchoconstriction induced by movement, treat pruritus concomitant with allergic rhinitis, urticaria and skin diseases, and the like. The composition has better curative effect compared with that the two medicines are used independently.

The present invention provides allergy and allergic reaction inhibitors, specifically the compound of the present invention as described in the following chemical formula I. The method for treating allergic reaction or allergic reaction disease or disorder comprises administering to a subject in need thereof for treatment An effective amount of a composition comprising a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof and a pharmaceutically acceptable carrier, vehicle or excipient.

The invention discloses an oral compound traditional Chinese medicine preparation for preventing poultry chill cold and flu. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight through even mixing: 120-200 parts of schizonepeta, 50-80 parts of ox horn wire, 15-35 parts of taurine, 20-60 parts of shikimic acid, 80-150 parts of gypsum, 1-3 parts of borneol, 80-150 parts of mint, 80-150 parts of herba violae, 30-80 parts of rhizoma phragmitis, and 10-50 parts of isatis root. The compound preparation is compounded by adopting traditional Chinese medicine extracts and traditional Chinese medicine powder with unique effects, has the effects of diminishing inflammation, killing bacteria, resisting virus, strengthening heart, relieving cough, resisting allergic reaction, improving poultry disease resisting immunity, repairing damaged mucous membranes and effectively controlling secondary infection, and has efficient treating effect on the poultry influenza and flu. The oral compound traditional Chinese medicine preparation has the advantages of reasonable and scientific formula, simple preparation, prominent effect and wide application, and can be used as the priority drug for preventing and treating the poultry influenza and flu.

The invention relates to a water-containing liquid bacterin preparation and the purpose thereof for treating and preventing allergic reaction. The preparation contains an allergen extract which exists in water-containing liquid or suspension containing a protein stabilizer and derives from one or more kinds of artemisia plant pollen.

The invention provides acylated glycoside compounds as well as a production method and application thereof. The acylated glycoside compounds are characterized by comprising the following structural general formula: R1 is H, OH or OAc and R2 is toluenesulfonyl group and salicyl. The acylated glycoside compounds disclosed by the invention have an immune regulation function and can be used for preparing medicaments for treating rheumatoid arthritis, medicaments for treating autoimmune diseases such as systemic lupus erythematosus, eczema and parapsoriasis guttata as well as medicaments for treating various immunological diseases such as allergic reaction.

The present invention discloses a Chinese medicine for curing allergic rhinitis. It is made up by using (by wt%) 10-50% of centipede, 10-50% of ligusticum root, 5-20% of asarum, 5-20% of magnolia flower and 5-20% of scutellaria root through a certain preparation process. Said invention also provides its preparation process and concrete steps. Said medicine can be made into nose drops and nose spray preparation.

The invention discloses an application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction. Pyrroloquinoline quinone can relieve allergic airway inflammation through antioxidant and anti-inflammatory effects, and is a potential novel medicine for the treating asthma. Pyrroloquinoline quinone has high antioxidant and anti-inflammatory effects. The in-vivo and in-vitrostudies carried out by the invention show that pyrroloquinoline quinone can reduce allergic airway inflammation by improving the immune microenvironment and regulating a JAK-STAT signaling pathway, and research shows that pyrroloquinoline quinone is safe for oral administration, so that pyrroloquinoline quinone is a potential novel medicine for treating asthma. Pyrroloquinoline quinone exists naturally in nature and can be supplemented by diet, the safety is good, the side effects are low, and the accessibility is high. Pyrroloquinoline quinone is a non-glucocorticoid immunomodulator that targets an asthma inflammatory pathway, the mechanism of medicine action is different from that of current medicines for treating asthma, and mutual complementing can be carried out.

The invention relates to the technical field of cosmetics, and discloses a plant extract composition with an anti-allergy effect and a preparation method. The composition comprises, in percentage by weight, 1%-50% of the extract of radix stephaniae tetrandrae, 1%-50% of the extract of radix gentianae and 1%-50% of the extract of liquorice roots. The composition formed by compounding the plant extracts can inhibit allergic reaction from multiple ways and reduce inflammation, and the composition can more effectively exert anti-allergy effect; the plant extract composition with the anti-allergy effect is extracted by taking a deep eutectic solvent as an extraction solvent; and the method has the characteristic of high extraction efficiency compared with a traditional water extraction method or a simple water-alcohol combined extraction method, and the anti-allergy effect of the extract is more remarkable.

The invention relates to an application of sulfated chlorella and spirulina composite polysaccharides in the immunoloregulation field. The sulfated composite polysaccharides have immunoloregulation activity, can enhance the neutral red phagocytosis ability of macrophages in mice, can improve the NO production ability of the macrophages and significantly improve the proliferation of splenic lymphocytes in the mice, and can improve the DNFB induced delayed allergy of the mice to enhance the immunity of the mice.

The invention relates to extract of the steroid saponin produced from the yam or the yam with the guilder leaf which has the character of containing the 80%-90% the steroid saponin in the percentage by weight. The intravenous fluid produced from the extract of the steroid saponin can not only dilate the coronary, depress the myocardial oxygen consumption, melt the thrombus, improve the myocardial ischemia and the microcirculation, amend the function of the vas endothelial cell, increase the blood stream of the brain, prevent the ischemia brain cell injury, but also drop the blood pressure, the blood fat, the blood sugar; at the same time, it has the function of resisting inflammation, ease pain, codein, preventing asthma, dispelling the myospasm, improving the immunity and resisting the allergy. So it can cure the cerebrovascular, the rheumatism and the disease of the respiratory system. The invention has the good clinic extended value because of the low dosage of the active ingredient, the efficacy, the effecting quick and the high bioavailability.

The invention discloses compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry. The soluble powder is prepared by uniformly mixing the following components in percentage by weight: 2-10 percent of levofloxacin hydrochloride, 2-10 percent of azithromycin, 2-6 percent of venenum bufonis, 10-30 percent of liquorice extract, 3-9 percent of Kameiding, 1-5 percent of trimethoprim lactate, and the balance of pharmaceutically applicable auxiliaries. The compound preparation is compounded by latest market medicines, traditional Chinese medicinal extracts, novel antiasthmatic drugs and medicinal synergistic agents, and fatal factors are comprehensively taken, so that the compound levofloxacin hydrochloride soluble powder has the effects of anti-inflammation, sterilization, anti-virus, heart strengthening, cough relieving and allergic reaction resistance, can be used for improving the anti-disease immunity of poultry, repairing injured mucous membrane and effectively controlling secondary infection, and has an effective treatment effect to respiratory diseases of poultry.

The invention discloses an application of honokiol in inhibiting streptococcus suis or a biofilm of the streptococcus suis. The inventors find that the honokiol or a pharmaceutically acceptable salt of the honokiol has the effect of inhibiting the formation of the streptococcus suis and the biofilm or killing the streptococcus suis in the mature biofilm; the inventors use a standard micro-dilutionmethod to measure the MIC value of the honokiol against the streptococcus suis, and results show that the MIC value of the honokiol against the streptococcus suis is close to the MIC value of antibiotics; and the inventors use a high-throughput static biofilm system method to construct an in-vitro biofilm model, and find that the subinhibitory-concentration honokiol can reduce the formation of the streptococcus suis biofilm and destroy the three-dimensional structure of the streptococcus suis biofilm through research results of a crystal violet method and scanning electron microscopy. The invention discloses a pharmaceutical composition for inhibiting the streptococcus suis or the biofilm by using the honokiol as a main active ingredient, and the pharmaceutical composition has good safety, and does not have the problems of drug residues, bacterial drug resistance, allergic reactions and gastrointestinal bleeding.

The invention relates to the medical technique field and discloses an application for preparing IV-type allergic response resistance medicament of an extract of ramulus euonymi which is a celastraceae plant. The animal models (sheep red blood cell causing mice delayed type pedal swelling, olive oil causing mice dermatitis contacta, 5-HT causing rat mastocyte in abdominal cavity releasing histamine, 5-HT inducing guinea pig ileum shrinking) which are broadly used for screening IV-type allergic response resistance in at home and abroad at present, verifies that the extract of the ramulus euonymi can obviously inhibit the mice delayed type pedal swelling caused by sheep red blood cells, the mice dermatitis contacta caused by olive oil, the rat mastocyte in abdominal cavity releasing histamine caused by 5-HT and the guinea pig ileum shrinking caused by 5-HT, thereby proving that the ramulus euonymi has exact effect in resisting IV-type allergic response, and therefore the ramulus euonymi can be used for preparing IV-type allergic response resistance medicament.

The present invention relates to specific skin reagent for diagnosing tuberculous infection and active tuberculosis, and belongs to the field of medical immunological diagnosis technology. The specific skin reagent consists of diluent liquid and dissolved tuberculous allergen, and the tuberculous allergen is tuberculous mycobacterium ESAT6 protein. The present invention also proposes applying tuberculous mycobacterium ESAT6 protein for human skin test as tuberculous allergen to detect tuberculous infecting person and tuberculosis patient and identify the specific reaction of inoculated Calmette-Guerin bacillus vaccine. The present invention can induce the immune response of tuberculous infecting person. The reagent can induce delayed allergic reaction of tuberculous infecting person and can identify BCG inoculation from the allergic reaction of non-tuberculous mycobacterium and tuberculous mycobacterium infection.